This is unpublished
NIRVANA: Nicotinamide Riboside in SARS-CoV-2 patients for renal protection
Completed Studies
Pinned
Principal Investigator
Bryan Kestenbaum
Status
Completed
Investigator
What is the study?
This study is a pilot, double-blind, placebo-controlled, multicenter, interventional clinical trial with oral nicotinamide riboside (NR) 500 mg (versus placebo) twice daily for a total of 10 days in hospitalized participants with COVID-19. Researchers will collect bio-specimens from participants.
Study Results
Researchers have completed this study. The study found that supplementation with nicotinamide riboside (NR) and coenzyme Q10 (CoQ10) favorably altered gene sets associated with metabolism and immune/stress signaling. The paper is in-press at the Clinical Journal of the American Society of Nephrology.